Evidence map›Paper›PMID 32084321›Full record

ReviewAnnual review of analytical chemistry (Palo Alto, Calif.)2020

Emerging Standards and Analytical Science for Nanoenabled Medical Products.

Bryant C Nelson, Caterina Minelli, Shareen H Doak, Matthias Roesslein

Abstract readReview
In one paragraph

Review in Annual review of analytical chemistry (Palo Alto, Calif.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Bryant C NelsonNational Institute of Standards and Technology (NIST), Biosystems and Biomaterials Division, Gaithersburg, Maryland 20899, USA; email: bryant.nelson@nist.gov.
Caterina MinelliNational Physical Laboratory, Chemical and Biological Science Department, Teddington TW11 0LW, United Kingdom.
Shareen H DoakSwansea University Medical School, Institute of Life Sciences, Swansea SA2 8PP, Wales, United Kingdom.
Matthias RoessleinSwiss Federal Laboratories for Materials Science and Technology (EMPA), Materials Meet Life Department, CH-9014 St. Gallen, Switzerland.

Funding

Intramural NIST DOC 9999-NIST
6 · The paper itself

Abstract

Development and application of nanotechnology-enabled medical products, including drugs, devices, and in vitro diagnostics, are rapidly expanding in the global marketplace. In this review, the focus is on providing the reader with an introduction to the landscape of commercially available nanotechnology-enabled medical products as well as an overview of the international documentary standards and reference materials that support and facilitate efficient regulatory evaluation and reliable manufacturing of this diverse group of medical products. We describe the materials, test methods, and standards development needs for emerging medical products. Scientific and measurement challenges involved in the development and application of innovative nanoenabled medical products motivate discussion throughout this review.

Indexed as

Biological ProductsNanomedicineNanotechnologyBiological Productsdocumentary standardsdrug productsin vitro diagnosticsmeasurement assurancemedical devicesnanomedicine

Identifiers

PMID32084321
PMCPMC8221451

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.